Treatment of Androgenic Alopecia with topical Minoxidil
Brenner S, Tamir A
Dermatology Dept., Sourasky Medical Center, Tel Aviv.
Harefuah, 121: 9, 1991 Nov 1, 297-302
Hair Loss Study Abstract
Minoxidil, a vasodilator, was first marketed in 1979 as an oral antihypertensive. Since hypertrichosis occurred as an adverse effect in most patients treated, a 2% topical solution was developed for use in men with androgenic alopecia. It was approved by the American Food and Drug Administration and by the Israel Ministry of Health. A follow-up of 30 cases treated with the preparation is presented. Efficacy of treatment was assessed by hair counts in a marked area on the balding scalp, as well as by subjective evaluations of patients and physicians. The treatment was beneficial in 63%: balding was slowed in most, while in a minority hair density actually increased. However, in only 6.6% was dramatic cosmetic improvement achieved.
Language of Publication